Eikon Device

Eikon Therapeutics has a clinical pipeline led by EIK1001, a systemically administered co‑agonist of toll-like receptors TLR7/8 in Phase III trials for advanced melanoma. The drug has shown efficacy both as monotherapy and in combination with anti-PD-(L)1 agents across multiple tumor types. Other programs include a selective PARP1 inhibitor in Phase I trials for several solid tumors, a CNS‑penetrant PARP1 inhibitor about to enter Phase I studies targeting brain cancers, two androgen receptor antagonists in early development, and an internally derived WRN inhibitor being studied for MSI-high/DNA repair–deficient cancers. The company’s discovery engine leverages Nobel Prize-winning super-resolution microscopy integrated with automation and high-performance computing to visualize protein dynamics at unprecedented resolution[3][4][5].